Study of Galvokimig for moderate-to-severe COPD with chronic bronchitis
Part of Infections, Lungs & breathing clinical trials.
This study tests an experimental drug called Galvokimig (taken as a pill) to see if it can reduce COPD flare-ups and improve lung function in people with moderate to severe COPD and chronic bronchitis. It is for those who have had recent flare-ups and are already using maintenance inhalers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 40 and 80 years old.
- You have moderate to severe COPD with chronic bronchitis (regular cough with mucus).
- You have had at least 2 moderate flare-ups in the past year or 1 severe flare-up in the past 6 months.
- You are a current or former smoker with at least a 10 pack-year smoking history.
- You are on stable maintenance inhaler therapy (LABA + LAMA, with or without an ICS) for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called Galvokimig to see if it helps reduce lung infections and improve quality of life in adults with bronchiectasis (a condition where lung airways are damaged and fill with mucus). It is a 24 to 52 week treatment, and you will be monitored closely for safety and effectiveness.
This trial tests whether a new medication, galvokimig, can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with creams or ointments. The study will measure how well the drug works, its safety, and how it behaves in your body.
This trial tests a new medicine called lunsekimig for people with COPD that still causes flare-ups despite standard treatment. It focuses on people with higher blood eosinophils (a type of white blood cell). If you smoke or used to smoke and have had at least 2 moderate or 1 severe flare-up in the past year, this study may be an option.
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
This study tests a new injectable medicine called CM310 for people with moderate to severe COPD who have chronic bronchitis and frequent flare-ups, despite using standard inhalers. It aims to see if CM310 can reduce flare-ups and improve breathing by targeting a specific type of inflammation.
This trial tests a medicine called depemokimab for people with COPD and a specific type of inflammation (type 2). It aims to see if it can reduce flare-ups when added to standard inhaler therapy.
Hear when a new Chronic Obstructive Pulmonary Disease With Chronic Bronchitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.